Alopecia Universalis After Alemtuzumab Treatment for Multiple Sclerosis: A Two-Year Follow-Up of Two Patients

    Giovanna Borriello, Antonio Ianniello, Ahmed Toosy
    Studysummary This study reports two cases of Alopecia Universalis as a secondary autoimmune manifestation following Alemtuzumab treatment, highlighting the importance of screening and monitoring for such autoimmune responses.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Case of Alemtuzumab-Related Alopecia Areata Management in Multiple Sclerosis Neurology Neuroimmunology & Neuroinflammation · 2018
    2. Increased Prevalence of Vitamin D Deficiency in Patients with Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2018
    3. Review of Treatment for Alopecia Totalis and Alopecia Universalis International Journal of Dermatology · 2017

    Related research 5

    1. Case Report of Novel Combination of Anthralin and Calcipotriene Leading to Trichologic Response in Alopecia Areata JAAD case reports · 2019
    2. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    3. Linear Alopecia Areata JAAD case reports · 2018
    4. Treating Resistant Cases of Alopecia Universalis Journal of cosmetology & trichology · 2018
    5. Overview of Alopecia Areata ˜The œjournal of investigative dermatology. Symposium proceedings/˜The œJournal of investigative dermatology symposium proceedings · 2013